Key Takeaways DHR's bioprocessing orders rose for the eighth straight quarter in Q2 2025.Biotechnology segment revenues grew 6%, driven by demand for mAbs.Life Sciences revenues fell 2.5% as academic and government demand weakened.Danaher Corporation (DHR) has been witnessing solid momentum in its bioprocessing business, driven by an increase in demand for consumables from large pharmaceutical customers in Europe. In the second quarter of 2025, orders in the bioprocessing business increased for the eighth c ...